skip to Global Navigation Bar skip to main content

homeHome > About Us > Recruitment > News


News Content
Daewoong Pharmaceutical ‘Nabota’ enters phase 3 clinical studies in China during the second half.
Date 2019-03-13 Hit 1890
News List
Prev Daewoong Pharmaceutical selected for government funding for DWN12088, a new medication for pulmonary fibrosis.
Next A global symposium pays attention to Nav 1.7 Chronic Pain Treatment, DWP17061.